Article

CD4 TCRBV CDR3 analysis in prevalent SLE cases from two ethnic groups.

Center for Blood Research, Harvard Medical School, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Lupus (impact factor: 2.34). 02/1999; 8(4):311-9. pp.311-9
Source: PubMed

ABSTRACT We examined CD4+ T cell TCRBV-CDR3 transcripts from 19 lupus patients and 16 controls to test the hypothesis that CD4+ TCRBV-CDR3 expression in SLE differs from normals. Within the disease group we also performed exploratory analyses to determine the association between risk of oligoclonality and HLA-DRB specificities and the duration of the CDR3 patterns. Oligoclonal patterns consistent with CDR3 restriction were three times more likely in SLE than in controls (OR = 3.7). TCRBV1, BV4, BV5.1, BV7, BV9, BV18 and BV22 gene segment CDR3 patterns of oligoclonality were seen exclusively among lupus patients. HLA-DRB3 increased the risk of oligoclonal expression in SLE. In four patients studied over time, the pattern of TCRBV-CDR3 expression was stable in a second sample obtained 6-14 months later. The increased frequency of CD4+ T cell TCRBV-CDR3 oligoclonal expression in SLE when compared to controls and the persistence of these patterns are consistent with an expanded pool of autoreactive CD4 T cells in SLE which recognize peptides derived from autoantigens. The association of HLA-DRB3 genes with increased risk of CDR3 oligoclonality among the SLE subjects is compatible with the hypothesis that molecules encoded by HLA-DRB3 may facilitate autoantigen recognition by CD4 T cells.

0 0
 · 
0 Bookmarks
 · 
18 Views

Keywords

16 controls
 
19 lupus patients
 
autoreactive CD4 T cells
 
BV22 gene segment CDR3 patterns
 
CD4 T cells
 
CD4+ T cell TCRBV-CDR3 oligoclonal expression
 
CD4+ T cell TCRBV-CDR3 transcripts
 
CD4+ TCRBV-CDR3 expression
 
CDR3 oligoclonality
 
CDR3 restriction
 
expanded pool
 
exploratory analyses
 
HLA-DRB specificities
 
lupus patients
 
molecules encoded
 
oligoclonal expression
 
Oligoclonal patterns consistent
 
recognize peptides
 
second sample
 
TCRBV-CDR3 expression
 

P A Fraser